Patients with Muscle-Invasive Bladder Cancer with Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most from Platinum-Based Neoadjuvant Chemotherapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patients with Muscle-Invasive Bladder Cancer with Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most from Platinum-Based Neoadjuvant Chemotherapy
Authors
Keywords
-
Journal
Clinical Genitourinary Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-03
DOI
10.1016/j.clgc.2023.10.014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer
- (2023) Ruihui Xie et al. CANCER RESEARCH
- Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
- (2023) Stéphane Culine et al. Cancers
- Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314
- (2023) Yi-Tsung Lu et al. European Urology Oncology
- Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
- (2022) Christian Pfister et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer
- (2022) N. Beije et al. ESMO Open
- Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer
- (2022) Alberto Gil-Jimenez et al. EUROPEAN UROLOGY
- Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment
- (2022) Thorsten H. Ecke et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy
- (2021) Mathieu Roumiguie et al. Nature Communications
- Tumor cell invasion in blood vessels assessed by immunohistochemistry is related to decreased survival in patients with bladder cancer treated with radical cystectomy
- (2021) Birgitte Carlsen et al. Diagnostic Pathology
- Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
- (2021) Gottfrid Sjödahl et al. EUROPEAN UROLOGY
- Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy
- (2021) Yair Lotan et al. JOURNAL OF UROLOGY
- Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy
- (2020) Guillaume Ploussard et al. Journal of Clinical Medicine
- Noninvasive Detection of Urothelial Carcinoma by Cost-effective Low-coverage Whole-genome Sequencing from Urine-Exfoliated Cell DNA
- (2020) Shuxiong Zeng et al. CLINICAL CANCER RESEARCH
- Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer
- (2020) Xu Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical implications of molecular subtyping in bladder cancer
- (2019) Uttam Satyal et al. CURRENT OPINION IN UROLOGY
- Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival
- (2019) Petter Kollberg et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer
- (2019) Alberto Martini et al. CANCER
- Choline-phosphate cytidylyltransferase-α as a possible predictor of survival and response to cisplatin neoadjuvant chemotherapy in urothelial cancer of the bladder
- (2018) Tammer Hemdan et al. Scandinavian Journal of Urology
- Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2
- (2018) Xu Chen et al. CLINICAL CANCER RESEARCH
- Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?
- (2018) Elio Mazzone et al. Cancer Epidemiology
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
- (2017) Roland Seiler et al. EUROPEAN UROLOGY
- Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis
- (2017) Bimal Bhindi et al. EUROPEAN UROLOGY
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
- (2017) Sam S. Chang et al. JOURNAL OF UROLOGY
- Prognostic Significance of Lymphovascular Invasion in Radical Cystectomy on Patients with Bladder Cancer: A Systematic Review and Meta-Analysis
- (2014) Hwanik Kim et al. PLoS One
- Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy
- (2013) Stephen H. Culp et al. JOURNAL OF UROLOGY
- Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer
- (2011) Robert Rosenblatt et al. EUROPEAN UROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation